Publication Topic

Perry CS, Verwiel AH, Covington TR, Proctor DM. 2024. PBPK modeling demonstrates that exposure time adjustment is unnecessary for setting an acute manganese inhalation exposure guideline. Regul Toxicol Pharmacol 153(Nov):105698; doi: 10.1016/j.yrtph.2024.105698. PMID: 39251127.

Mittal L, Perry CS, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Anal. 44(9):2169-2186. doi: 10.1111/risa.14309. PMID: 38622492.

Covington TR, Sterner TR. Physiologically-based pharmacokinetic model to predict HFC-134a in exhaled breath following albuterol inhaler use. Poster presented at the Society of Toxicology Annual Meeting, Nashville, TN, March 2023.

Sterner TR, Covington TR, Mattie DR. 2023. Complex mixtures: Array PBPK modeling of jet fuel components. Toxics 11(2):187; doi: 10.3390/toxics11020187. PMID: 36851061.

Pouillot R, Farakos SS, Spungen J, Schaefer HR, Flannery BM, Van Doren JM. 2022. Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population. Toxicol Lett 367(Aug):67-75; doi: 10.1016/j.toxlet.2022.07.812. PMID: 35901988. Corrigendum: Toxicol Lett 2023 377(March):14-15; doi: 10.1016/j.toxlet.2023.01.011.

Yoon M, Ring C, Van Landingham CB, Suh M, Song G, Antonijevic T, Gentry PR, Taylor MD, Keen AM, Andersen ME, Clewell JH. 2019. Assessing children’s exposure to manganese in drinking water using a PBPK model. Toxicol Appl Pharmacol 380(Oct 1):114695; doi: 10.1016/j.taap.2019.114695.

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Covington TR, Lumley LA, Ruark CD, Clarkson ED, Whalley CE, Gearhart JM. 2016. Modeling organophosphorus chemical warfare nerve agents: A physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) model of VX. In: Worek F, Jenner J, Thiermann H (eds), Chemical Warfare Toxicology: Volume 1: Fundamental Aspects, pp. 213–263. Royal Society of Chemistry.

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Kirman CR, Proctor D, Suh M, Thompson CM, Harris MA, Haws LC, Hays SM. Variation analysis of PBPK model parameters for describing the delivery of Cr(VI) to the small intestines of humans. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Knutsen JS, Kerger BD, Finley BL, Paustenbach DJ. 2012. A calibrated human PBPK model for benzene inhalation with urinary bladder and bone marrow compartments. Risk Anal 33 (7):1237–1251; doi: 10.1111/j.1539-6924.2012.01927.x. PMID: 23278103.

Sterner T, Ruark C, Covington T, Gearhart J. Monte Carlo and sensitivity analyses of a PBPK model for the oxime TMB-4. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Las Vegas, NV, November 2011.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Johns DO, Owens EO, Thompson CM, Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.